RxDoctor Payments Data

Tracey Wiese

Family · Anchorage, AKNPI 1467781021

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $510, 9.8 times the $52 reported in 2021.

$989in general payments, 2019–2025

Across 46 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$184
  • Supernus Pharmaceuticals, Inc.$164
  • Viiv Healthcare Company$142
  • Gilead$140
  • Neurocrine Biosciences, Inc.$86
  • Otsuka America Pharmaceutical, Inc.$68
  • plus $205 from 7 others

What the payments were for

  • Food & beverage$989100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$989 in reported general payments places this provider in the 75th percentile of 315 family providers in Alaska.

See all family providers in Alaska →

Medicare billing

Part B allowed, 2024
$17,064
Medicare patients
48
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ziprasidone Hcl14$1,022
Dextroamphetamine Sulfate11$835
Hydroxyzine Hcl21$339
Duloxetine Hcl28$332
Prazosin Hcl17$210
Alprazolam18$32

Paid to pharmacies, not to this prescriber.

Other family in Anchorage

See the full list for Alaska →

Where these figures come from

Is this you, or does something look wrong? →